Rimegepant
Rimegepant is a medication for the treatment of an acute migraine with or without aura in adults. It is not used prophylactically.
Taken by mouth to dissolve on or under the tongue, rimegepant takes effect within an hour and can provide relief from migraine headache for up to 48 hours. It is not a narcotic and has no addictive potential; thus it is not designated as a controlled substance. It works by blocking CGRP receptors.
Approved for use in the United States in February 2020, rimegepant is produced and marketed by Biohaven Pharmaceuticals, based in New Haven, Connecticut.Mechanism of action
Rimegepant is a small molecule calcitonin gene-related peptide receptor antagonist.History
Originally discovered at Bristol-Myers Squibb, rimegepant was developed by Biohaven Pharmaceuticals, which now markets the drug in the United States after receiving FDA approval in February 2020. Approval was based on evidence from one clinical trial of 1,351 subjects with migraine headaches.
